JPWO2022177835A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022177835A5 JPWO2022177835A5 JP2023548591A JP2023548591A JPWO2022177835A5 JP WO2022177835 A5 JPWO2022177835 A5 JP WO2022177835A5 JP 2023548591 A JP2023548591 A JP 2023548591A JP 2023548591 A JP2023548591 A JP 2023548591A JP WO2022177835 A5 JPWO2022177835 A5 JP WO2022177835A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- acceptable salt
- treated
- previously
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- GQCXHIKRWBIQMD-AKJBCIBTSA-N 3-[(1R,3R)-1-[2,6-difluoro-4-[[1-(3-fluoropropyl)azetidin-3-yl]amino]phenyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluoropropan-1-ol Chemical compound FC1=C(C(=CC(=C1)NC1CN(C1)CCCF)F)[C@H]1N([C@@H](CC2=C1NC1=CC=CC=C21)C)CC(CO)(F)F GQCXHIKRWBIQMD-AKJBCIBTSA-N 0.000 claims 4
- 229940126088 GDC-9545 Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 claims 4
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 claims 4
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 3
- 102000015694 estrogen receptors Human genes 0.000 claims 3
- 108010038795 estrogen receptors Proteins 0.000 claims 3
- 229950006331 ipatasertib Drugs 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960002258 fulvestrant Drugs 0.000 claims 2
- 229960003881 letrozole Drugs 0.000 claims 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims 1
- 102000015433 Prostaglandin Receptors Human genes 0.000 claims 1
- 108010050183 Prostaglandin Receptors Proteins 0.000 claims 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229960004390 palbociclib Drugs 0.000 claims 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163149947P | 2021-02-16 | 2021-02-16 | |
| US63/149,947 | 2021-02-16 | ||
| PCT/US2022/016254 WO2022177835A1 (en) | 2021-02-16 | 2022-02-14 | Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024506347A JP2024506347A (ja) | 2024-02-13 |
| JPWO2022177835A5 true JPWO2022177835A5 (https=) | 2025-02-18 |
| JP2024506347A5 JP2024506347A5 (https=) | 2025-02-18 |
Family
ID=80682672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548591A Pending JP2024506347A (ja) | 2021-02-16 | 2022-02-14 | Ｇｄｃ－９５４５およびイパタセルチブを含む併用療法を使用する乳がんの処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230381156A1 (https=) |
| EP (1) | EP4294393A1 (https=) |
| JP (1) | JP2024506347A (https=) |
| CN (1) | CN116847839A (https=) |
| TW (1) | TWI881203B (https=) |
| WO (1) | WO2022177835A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115872996B (zh) * | 2023-02-21 | 2023-05-05 | 山东绿叶制药有限公司 | 一种雌激素受体降解剂化合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170362228A1 (en) * | 2016-06-16 | 2017-12-21 | Genentech, Inc. | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF |
| LT3810283T (lt) * | 2018-06-21 | 2023-08-25 | F. Hoffmann-La Roche Ag | 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti |
| CA3109090A1 (en) | 2018-08-17 | 2020-02-20 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for the treatment of breast cancer |
| CN113194941A (zh) * | 2018-12-19 | 2021-07-30 | 基因泰克公司 | 使用包括akt抑制剂、紫杉烷和pd-l1抑制剂的组合疗法治疗乳腺癌 |
-
2022
- 2022-02-14 JP JP2023548591A patent/JP2024506347A/ja active Pending
- 2022-02-14 TW TW111105229A patent/TWI881203B/zh active
- 2022-02-14 EP EP22708657.6A patent/EP4294393A1/en active Pending
- 2022-02-14 CN CN202280012941.XA patent/CN116847839A/zh active Pending
- 2022-02-14 WO PCT/US2022/016254 patent/WO2022177835A1/en not_active Ceased
-
2023
- 2023-08-15 US US18/449,807 patent/US20230381156A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024015120A5 (https=) | ||
| JP2019529581A5 (https=) | ||
| JP2019508476A5 (https=) | ||
| TW202304424A (zh) | 包含依維莫司和安森司群的組合 | |
| EP4322941A1 (en) | Combination comprising ribociclib and amcenestrant | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| JP2022544485A (ja) | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 | |
| JP2021512906A5 (https=) | ||
| IL295807A (en) | A combination of alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[ 7]annulene-2-carboxylic acid | |
| JP2024542633A (ja) | がん治療用ｃｄｋ４阻害剤 | |
| JP2023175688A5 (https=) | ||
| JP2024102045A5 (https=) | ||
| EP1383495A1 (en) | Duloxetine for treatment of hot flashes | |
| JP2011506607A5 (https=) | ||
| JP2022177119A5 (https=) | ||
| JPWO2022177835A5 (https=) | ||
| JP2021503448A5 (https=) | ||
| AU2017251804A1 (en) | Pharmaceutical combinations comprising a PI3K inhibitor for the treatment of cancer | |
| JPWO2021030248A5 (https=) | ||
| JPWO2021007146A5 (https=) | ||
| CN118338901A (zh) | 用于治疗癌症的cdk4抑制剂 | |
| US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
| JPWO2022177844A5 (https=) | ||
| JPWO2020097625A5 (https=) | ||
| JP2023086719A5 (https=) |